Immuno-oncology company Nouscom, a developer of off-the-shelf and personalised neoantigen-based genetic cancer vaccines based on its proprietary technology platform, revealed on Monday that John F McDonald has been appointed to its board of directors, as an independent director.
With over 25 years experience in corporate, legal, business development and venture capital in the pharmaceutical and biotech industries, McDonald has expertise that involves academic institutions and biotech and pharmaceutical companies of all stages, including financing, acquisitions, R&D collaborations and in-licensing agreements, among others, the company stated.
McDonald is currently Corporate VP, Global Business Development at Novo Nordisk.
Previously, he served as VP Business Development at Biogen Inc, managing director at healthcare investment firm MPM Capital and VP Business Development at Millennium Pharmaceuticals.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine